S039 What's New in Dermatopathology
DESCRIPTION
This symposium provides information regarding advances in key areas of dermatopathology. Cutaneous neoplasia, inflammatory skin disease, dermoscopy, molecular techniques, translational research, and cutaneous infections will be covered. Attendees will leave the session with updated knowledge in dermatopathology.
LEARNING OBJECTIVES
Describe new advances in cutaneous neoplasia, including melanocytic tumors and adnexal neoplasms
Discuss recent developments in immunobullous disorders and cutaneous drug reactions
Describe need-to-know patterns of dermoscopy.
SCHEDULE
1:00 PM
Introduction
Jeffrey P. North, MD, FAAD
1:05 PM
Updates in immunodermatology
Julia S. Lehman, MD, FAAD
1:25 PM
Updates in cutaneous drug reactions
Emily Y. Chu, MD, PhD, FAAD
1:45 PM
Granulomas gone wild: Rubella as a trigger in granulomatous disease
Karolyn Wanat, MD, FAAD
2:05 PM
Updates in diagnosing pigmentary disorders
Anisha Patel, MD, FAAD
2:25 PM
Q&A
Emily Y. Chu, MD, PhD, FAAD, Julia S. Lehman, MD, FAAD, Anisha Patel, MD, FAAD, Karolyn Wanat, MD, FAAD
2:40 PM
Updates in melanocytic neoplasia
Iwei Yeh, MD, PhD, FAAD
3:00 PM
Updates in Inpatient dermatopathology
Kiran Motaparthi, MD, FAAD
3:20 PM
Correlating histopathology with dermoscopy
Michelle B Tarbox, MD, FAAD
3:40 PM
Q&A
Kiran Motaparthi, MD, FAAD, Michelle B Tarbox, MD, FAAD, Iwei Yeh, MD, PhD, FAAD
DIRECTOR
Jeffrey P. North, MD, FAAD
SPEAKERS
Emily Y. Chu, MD, PhD, FAAD
Julia S. Lehman, MD, FAAD
Kiran Motaparthi, MD, FAAD
Anisha Patel, MD, FAAD
Michelle B Tarbox, MD, FAAD
Karolyn Wanat, MD, FAAD
Iwei Yeh, MD, PhD, FAAD
HANDOUTS
DISCLOSURES
Emily Y. Chu, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Julia S. Lehman, MD, FAAD
argenx – Consultant (1099 relationship)(Honoraria);
Kiran Motaparthi, MD, FAAD
Castle Biosciences, Inc – Consultant(Fees), Investigator(Grants/Research Funding); Proscia – Investigator(Grants/Research Funding);
Jeffrey P. North, MD, FAAD
Johnson & Johnson Pharmaceutical Research & Development – Consultant (1099 relationship)(Fees);
Anisha Patel, MD, FAAD
AnaptysBio – Investigator(Grants/Research Funding); Asymmetric Therapeutics, LLC – Consultant (1099 relationship)(Fees); Deciphera Pharmaceuticals, Inc. – Consultant(Fees); Erasca – Consultant (1099 relationship)(Fees); Hoth Therapeutics – Investigator(Grants/Research Funding); Janssen Scientific Affairs, LLC – Consultant (1099 relationship)(Fees); Lutris – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Novartis – Advisory Board(Fees), Other(No Compensation Received); OnQuality Pharmaceuticals, Ltd. – Consultant(Fees), Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); Repare therapeutics – Consultant (1099 relationship)(Fees); SynOx Therapeutics – Consultant (1099 relationship)(Fees);
Michelle B Tarbox, MD, FAAD
Castle Biosciences – Investigator(Grants/Research Funding); Novartis – Advisory Board(Honoraria); Sanofi/Regeneron – Investigator(Grants/Research Funding);
Karolyn Wanat, MD, FAAD
No financial relationships exist with ineligible companies.
Iwei Yeh, MD, PhD, FAAD
23andMe – Founder(Stock); Pfizer Inc. – Investigator(Grants/Research Funding);